AIDS Research and Therapy (Apr 2009)

Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture

  • Dutschman Ginger E,
  • Grill Susan P,
  • Paintsil Elijah,
  • Cheng Yung-Chi

DOI
https://doi.org/10.1186/1742-6405-6-5
Journal volume & issue
Vol. 6, no. 1
p. 5

Abstract

Read online

Abstract Background Most in vitro assays of drug potency may not adequately predict the performance in vivo. Methods to assess the persistence of antiviral activity of deoxynucleoside analogs, which require intracellular activation to the active metabolites that can persist in cells, will be important for designing dosages, combination regimens, and assessing treatment compliance. Using an HIV-IIIB/TZM-bl indicator cell culture system, we assessed the ability of an inhibitor to protect cells from infection and to delay viral rebound after removal of inhibitor from culture. Results The order of protection of cells from HIV-infection was 4'-Ed4T > LFD4C > DDI > D4T > 3TC > AZT > FTC > NVP. The fold-increase in EC50 to delay viral rebound was DDI 4'-Ed4T > LFD4C > FTC = D4T > 3TC > NVP > AZT. Conclusion The persistence ranking was derived from assays based on measures of single viral replication-cycle and cumulative inhibition at multiple time-points. Therefore, a better indicator of the pharmacodynamic property of an inhibitor. The persistence of anti-HIV activity assay may complement in vitro potency assays to better predict in vivo performance of nucleoside analogs.